Stephanie Fox-Rowlings May 24 2017: FDA should only approve new treatments when there is clear proof they are safe and helpful. If many people drop out of the study, it’s hard to know if the drug really works, and the FDA should not approve it without strong evidence.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony to FDA About Neratinib to Prevent Breast Cancer Reccurance
The National Center for Health Research advises the FDA to delay approval of neratinib for early-stage HER2-positive breast cancer, highlighting that the drug offers only a slight improvement in preventing cancer recurrence while causing serious side effects like severe diarrhea and fatigue, which led many patients to stop treatment.
Read More »Nonprofit Groups’ Letter to Secretary Price on the Tobacco “Deeming Rule”
May 17, 2017. In light of the overwhelming record evidence compiled by the FDA, there is no public health justification for the FDA to reconsider the deeming rule, or to postpone the implementation of its provisions.
Read More »Coalition Letter Supporting Smoke-Free VA Facilities
May 11, 2017. We write in support of H.R. 1662, which would make facilities of the Veterans Health Administration (VHA) smoke-free.
Read More »NCHR Testimony at FDA Meeting about Duchenne Muscular Dystrophy Clinical Trial
May 18, 2017. Patients with Duchenne muscular dystrophy and their loved ones deserve the benefits of the most rigorous research available. At the same time, investing in a clinical trial requires significant time and effort, and patients ALWAYS face risks without any guarantee of benefits. Patients and families who are willing to participate in a clinical trial that has the potential to benefit many should be fully informed about the potential risks and benefits of their participation in order to make a decision that is best for them.
Read More »